BHVN:NYE-Biohaven Pharmaceutical Holding Co Ltd (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 147.76

Change

+0.15 (+0.10)%

Market Cap

USD 10.55B

Volume

0.43M

Avg Analyst Target

USD 149.50 (+1.18%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

BHVN Stock Forecast & Price:
Based on the Biohaven Pharmaceutical Holding Co Ltd stock forecasts from 7 analysts, the average analyst target price for Biohaven Pharmaceutical Holding Co Ltd is USD 149.50 over the next 12 months. Biohaven Pharmaceutical Holding Co Ltd’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Biohaven Pharmaceutical Holding Co Ltd is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Biohaven Pharmaceutical Holding Co Ltd’s stock price was USD 147.76. Biohaven Pharmaceutical Holding Co Ltd’s stock price has changed by +0.53% over the past week, +1.90% over the past month and +30.82% over the last year.

About Biohaven Pharmaceutical Holding Co Ltd (BHVN:NYE)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as ...Read More

Company Website : https://www.biohavenpharma.com

Address : 215 Church Street, New Haven, CT, United States, 06510

Employees : 928

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.03

52 Week High : 151.51

Short Ratio : 5.69

52 Week Low : 79.01

Shorted Shares : 5,214,821

200 Day Moving Average : 128.41

Shorted Shares Previous Month : 4,452,975

50 Day Moving Average : 145.43

Shares Held By Insiders : 11.56%

Short Percentage : 8.13%

Shares Held by Institutions : 84.89%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

-1.29 (-1.19%)

 USD241.26B 35.31 3.25
TECH Bio-Techne Corp

+5.22 (+1.39%)

 USD14.69B 56.48 37.68
DNA Ginkgo Bioworks Holdings

+0.23 (+6.76%)

 USD5.47B N/A -1.72
RCUS Arcus Biosciences Inc

+1.32 (+5.10%)

 USD1.95B 35.06 11.50
MYOV Myovant Sciences Ltd

+0.79 (+4.46%)

 USD1.70B N/A -12.54
ADCT Adc Therapeutics SA

+2.18 (+26.85%)

 USD0.62B -99,999.99 -1.65
PFNX Pfenex Inc

N/A

 USD0.44B 268.67 63.90
ZYME Zymeworks Inc

+0.46 (+6.60%)

 USD0.40B 300.20 -0.82
LCTX Lineage Cell Therapeutics Inc

+0.02 (+1.29%)

 USD0.25B 3.63 -4.17
MTNB Matinas BioPharma Holdings Inc

N/A

 USD0.19B N/A -5.90

ETFs Containing BHVN

Symbol Name Weight Mer Price(Change) Market Cap
BBSC JPMorgan BetaBuilders U.S.. 0.00 % 0.09 %

+1.14 (+1.95%)

 N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.22% 94% A 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.22% 94% A 85% B
Trailing 12 Months  
Capital Gain 26.73% 100% A+ 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.73% 100% A+ 91% A-
Trailing 5 Years  
Capital Gain 505.57% 86% B 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 505.57% 86% B 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 47.76% 82% B- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.76% 82% B- 94% A
Risk Return Profile  
Volatility (Standard Deviation) 37.27% 61% D- 28% F
Risk Adjusted Return 128.15% 100% A+ 99% A+
Market Capitalization 10.55B 94% A 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 31.82 10% F 2% F
Price / Cash Flow Ratio -12.70 94% A 89% B+
EV/EBITDA -14.79 100% A+ 91% A-
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 602.04% 100% A+ 99% A+
Return on Assets -35.83% 31% F 1% F
Debt to Equity Ratio -84.76% 100% A+ 96% A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 5.69 28% F 18% F
Short Percent 8.13% 23% F 34% F
Beta 1.03 62% D- 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector